E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic haemodialysis patients 18 years upwards. Patients should be in a stable condition during their chronic dialysis program (no ongoing infections or active extensive tumour with CRP above 30 mg/l). (men and women, not limited to a specific subdiagnose). Most women in the dialysis program are non fertile due to severe disturances of their hormone regulation.
|
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066622 |
E.1.2 | Term | <Manually entered code. Term in E.1.1> |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate if lipoprotein lipase and its inhibitors together with its lipid degradation products (i.e., triglycerides) are differently altered using Citrasate for dialysis (in the dialysate fluid only as a Medical device product) than using standard dialysis with tinzaparin as anticoagulant. |
|
E.2.2 | Secondary objectives of the trial |
May long term use of citrate containing dialysate improve lipid degradation in haemodialysis patients? |
|
E.2.3 | Trial contains a sub-study | No |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
This comparative study has no other substudy. |
|
E.3 | Principal inclusion criteria |
Initially 20 patients will be included in the study (one center). Eventually, if data indicate a non expected outcome (this is a first pilot study in this field), approximately up to 40 patients on chronic haemodialysis will be included in the study (2 centers). Age above 18 years and no restriction to gender or race. consecutively asked and included). |
|
E.4 | Principal exclusion criteria |
If patient refuses and if patient is in a poor physical and medical condition (i.e. ongoing inflamamtion of more extensive degree such as CRP above 40 mg/l). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
This is a paired (case-control) study where the same patient is investigated using two different routine haemodialysis settings. Blood sampling during dialysis is performed once using each established dialysis technique. It will be prformed as a randomized cross-over study with each patient as their own controls. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
The patient is her/his own control |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Citrasate (dialysis fluid) |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The patients proceed with their regular dialysis. These tests are prformed during regular dialysis with two various types of established dialysis procedures. Only two blood sampling episodes will occurr during their conventional dialysis therapy. Only two centers will be involved in the trial (Umea and Östersund in Sweden). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |